At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma
In Brief
A Phase 2 clinical trial evaluating Ipilimumab, Laboratory Biomarker Analysis, and 1 other intervention for Recurrent Melanoma and 4 related conditions. Active but no longer recruiting, targeting 88 participants across 277 sites.
Detailed Summary
This randomized phase II trial studies how well ipilimumab with or without high-dose recombinant interferon alpha-2b works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab, may block tumor growth by targeting certain cells. Recombinant interferon alfa-2b may interfere with the growth of tumor cells. It is not yet known whether ipilimumab is more effective with or without high-dose recombinant interferon alfa-2b in treating melanoma.
Study Details
Timeline
Interventions
Given IV
Correlative studies
Given IV or SC